Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Impact of Antifungal Compounds on Viability and Anti-Aspergillus Activity of Human Natural Killer Cells.

Schmidt S, Schubert R, Tramsen L, Lehrnbecher T.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01993-18. doi: 10.1128/AAC.01993-18. Print 2019 Feb.

2.

Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives.

Schmidt S, Tramsen L, Rais B, Ullrich E, Lehrnbecher T.

Oncotarget. 2018 Apr 17;9(29):20891-20907. doi: 10.18632/oncotarget.25058. eCollection 2018 Apr 17. Review.

3.

Impact of human mesenchymal stromal cells on antifungal host response against Aspergillus fumigatus.

Schmidt S, Tramsen L, Schneider A, Schubert R, Balan A, Degistirici Ö, Meisel R, Lehrnbecher T.

Oncotarget. 2017 Sep 8;8(56):95495-95503. doi: 10.18632/oncotarget.20753. eCollection 2017 Nov 10.

4.

Natural Killer Cells in Antifungal Immunity.

Schmidt S, Tramsen L, Lehrnbecher T.

Front Immunol. 2017 Nov 22;8:1623. doi: 10.3389/fimmu.2017.01623. eCollection 2017. Review.

5.

Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.

Tramsen L, Salzmann-Manrique E, Bochennek K, Klingebiel T, Reinhardt D, Creutzig U, Sung L, Lehrnbecher T.

J Clin Oncol. 2016 Aug 10;34(23):2776-83. doi: 10.1200/JCO.2016.66.7881. Epub 2016 Jun 6.

6.

Immunotherapeutic strategies against mucormycosis in haematopoietic stem cell transplantation.

Schmidt S, Tramsen L, Schneider A, Balan A, Lehrnbecher T.

Mycoses. 2014 Dec;57 Suppl 3:8-12. doi: 10.1111/myc.12241. Epub 2014 Sep 18. Review.

PMID:
25231156
7.

Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

Balan A, Lucchini G, Schmidt S, Schneider A, Tramsen L, Kuçi S, Meisel R, Bader P, Lehrnbecher T.

Leukemia. 2014 Oct;28(10):1941-8. doi: 10.1038/leu.2014.127. Epub 2014 Apr 3. Review.

PMID:
24762460
8.

Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells.

Tramsen L, Schmidt S, Roeger F, Schubert R, Salzmann-Manrique E, Latgé JP, Klingebiel T, Lehrnbecher T.

Infect Immun. 2014 Jun;82(6):2649-56. doi: 10.1128/IAI.01700-14. Epub 2014 Apr 7.

9.

No effect of antifungal compounds on functional properties of human antifungal T-helper type 1 cells.

Tramsen L, Schmidt S, Koehl U, Huenecke S, Latgé JP, Roeger F, Schubert R, Klingebiel T, Lehrnbecher T.

Transpl Infect Dis. 2013 Aug;15(4):430-4. doi: 10.1111/tid.12089. Epub 2013 May 6.

PMID:
23647945
10.

Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes.

Tramsen L, Schmidt S, Boenig H, Latgé JP, Lass-Flörl C, Roeger F, Seifried E, Klingebiel T, Lehrnbecher T.

Cytotherapy. 2013 Mar;15(3):344-51. doi: 10.1016/j.jcyt.2012.11.014.

PMID:
23579059
11.

Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients.

Lehrnbecher T, Schmidt S, Tramsen L, Klingebiel T.

Front Oncol. 2013 Feb 7;3:17. doi: 10.3389/fonc.2013.00017. eCollection 2013.

12.

Natural killer cells and antifungal host response.

Schmidt S, Zimmermann SY, Tramsen L, Koehl U, Lehrnbecher T.

Clin Vaccine Immunol. 2013 Apr;20(4):452-8. doi: 10.1128/CVI.00606-12. Epub 2013 Jan 30. Review.

13.

Immunotherapy in invasive fungal infection--focus on invasive aspergillosis.

Lehrnbecher T, Kalkum M, Champer J, Tramsen L, Schmidt S, Klingebiel T.

Curr Pharm Des. 2013;19(20):3689-712. Review.

PMID:
23278541
14.

Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity.

Schmidt S, Tramsen L, Perkhofer S, Lass-Flörl C, Hanisch M, Röger F, Klingebiel T, Koehl U, Lehrnbecher T.

Immunobiology. 2013 Jul;218(7):939-44. doi: 10.1016/j.imbio.2012.10.013. Epub 2012 Nov 2.

PMID:
23201314
15.

Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation.

Schmidt S, Tramsen L, Perkhofer S, Lass-Flörl C, Röger F, Schubert R, Lehrnbecher T.

J Infect Dis. 2012 Jul 1;206(1):135-9. doi: 10.1093/infdis/jis308. Epub 2012 Apr 23.

PMID:
22529315
16.

Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.

Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll AH, Lehrnbecher T.

Clin Microbiol Infect. 2011 Dec;17(12):1868-74. doi: 10.1111/j.1469-0691.2011.03483.x. Epub 2011 Sep 6.

17.

Immunotherapy against invasive fungal diseases in stem cell transplant recipients.

Lehrnbecher T, Tramsen L, Koehl U, Schmidt S, Bochennek K, Klingebiel T.

Immunol Invest. 2011;40(7-8):839-52. doi: 10.3109/08820139.2011.581732. Epub 2011 May 31.

PMID:
21627412
18.

Challenges and prospects of adoptive immunotherapy in prevention and treatment of opportunistic mycoses in hematologic transplant recipients.

Tramsen L, Schmidt S, Roeger F, Koehl U, Lehrnbecher T.

Curr Infect Dis Rep. 2010 Nov;12(6):444-9. doi: 10.1007/s11908-010-0130-3.

PMID:
21308553
19.

Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia.

Schmidt S, Tramsen L, Hanisch M, Latgé JP, Huenecke S, Koehl U, Lehrnbecher T.

J Infect Dis. 2011 Feb 1;203(3):430-5. doi: 10.1093/infdis/jiq062. Epub 2010 Dec 14.

20.

Adoptive antifungal T cell immunotherapy--into the clinic?

Lehrnbecher T, Schmidt S, Koehl U, Schuster FR, Uharek L, Klingebiel T, Tramsen L.

Med Mycol. 2011 Apr;49 Suppl 1:S164-9. doi: 10.3109/13693786.2010.497953. Epub 2010 Jun 30.

PMID:
20586680
21.

IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.

Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U.

J Immunother. 2010 Feb-Mar;33(2):200-10. doi: 10.1097/CJI.0b013e3181bb46f7.

PMID:
20145545
22.

10-Parameter flow cytometry as a new tool to improve diagnosis and MRD follow-up of acute leukemias.

Wehner S, Soerensen J, Schwabe D, Tramsen L, Quaritsch R, Esser R, Klingebiel T, Koehl U.

Klin Padiatr. 2009 Nov-Dec;221(6):393-5. doi: 10.1055/s-0029-1239535. Epub 2009 Nov 4. No abstract available.

PMID:
19890796
23.

Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.

Tramsen L, Koehl U, Tonn T, Latgé JP, Schuster FR, Borkhardt A, Uharek L, Quaritsch R, Beck O, Seifried E, Klingebiel T, Lehrnbecher T.

Bone Marrow Transplant. 2009 Jan;43(1):13-9. doi: 10.1038/bmt.2008.271. Epub 2008 Sep 1.

PMID:
18762764
24.

Cultivated anti-Aspergillus T(H)1 cells.

Lehrnbecher T, Beck O, Koehl U, Tramsen L.

Med Mycol. 2009;47 Suppl 1:S170-4. doi: 10.1080/13693780802169120. Epub 2008 Jun 10. Review.

PMID:
18651313
25.

Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood.

Beck O, Koehl U, Tramsen L, Mousset S, Latgé JP, Müller K, Schwabe D, Bader P, Klingebiel T, Lehrnbecher T.

J Immunol Methods. 2008 Jun 1;335(1-2):41-5. doi: 10.1016/j.jim.2008.02.014. Epub 2008 Mar 20.

PMID:
18395221
26.

Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies.

Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, Chanock SJ.

Lancet Oncol. 2008 Mar;9(3):269-78. doi: 10.1016/S1470-2045(08)70071-8. Review.

PMID:
18308252
27.

Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis.

Huenecke S, Behl M, Fadler C, Zimmermann SY, Bochennek K, Tramsen L, Esser R, Klarmann D, Kamper M, Sattler A, von Laer D, Klingebiel T, Lehrnbecher T, Koehl U.

Eur J Haematol. 2008 Jun;80(6):532-9. doi: 10.1111/j.1600-0609.2008.01052.x. Epub 2008 Feb 12.

PMID:
18284628
28.

Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey.

Simon A, Lehrnbecher T, Bode U, Groll AH, Tramsen L, Wieland R, Molitor E, Fleischhack G, Laws HJ.

Eur J Clin Microbiol Infect Dis. 2007 Nov;26(11):801-6.

PMID:
17786491
29.

Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant.

Tramsen L, Beck O, Schuster FR, Hunfeld KP, Latgé JP, Sarfati J, Röger F, Klingebiel T, Koehl U, Lehrnbecher T.

J Infect Dis. 2007 Aug 1;196(3):485-92. Epub 2007 Jun 18.

PMID:
17597464

Supplemental Content

Loading ...
Support Center